Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy.
We evaluated whether the increased immunogenicity provided by an MF59-adjuvant influenza vaccine translates into increased protection among the elderly. Residents of 25 long-term care facilities received either the adjuvant or a non-adjuvant vaccine. The odds ratios (OR) of influenza-like illness were calculated for non-adjuvant vs. adjuvant vaccine recipients, also stratifying for chronic cardiovascular, respiratory, and renal diseases. The risk was higher for the non-adjuvant vaccine recipients and highest for those with respiratory disease (OR 2.27, 95% CI 1.09-4.82) and cardiovascular disease (OR 1.88; 95% CI 1.31-2.72). In this study the MF59-adjuvant vaccine provided superior clinical protection among the elderly, especially those with chronic diseases.
Iob
A
A
Azienda Servizi Sanitari no. 3, Gemona, Alto Friuli, Italy. dip@ass3.sanita.fvg.it
Brianti
G
G
Zamparo
E
E
Gallo
T
T
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D016001:Confidence Intervals; D005260:Female; D005500:Follow-Up Studies; D006707:Homes for the Aged; D006801:Humans; D007115:Immunization Schedule; D015994:Incidence; D007252:Influenza Vaccines / Q000008:administration & dosage*; D007251:Influenza, Human / Q000453:epidemiology / Q000517:prevention & control*; D007558:Italy / Q000453:epidemiology; D008134:Long-Term Care; D008297:Male; D009735:Nursing Homes; D016017:Odds Ratio; D011136:Polysorbates / Q000008:administration & dosage*; D012307:Risk Factors; D012680:Sensitivity and Specificity; D017678:Sex Distribution; D013185:Squalene / Q000008:administration & dosage* / Q000276:immunology
D000276:Adjuvants, Immunologic; D007252:Influenza Vaccines; C089950:MF59 oil emulsion; D011136:Polysorbates; D013185:Squalene